Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Novarel Market Forecast Highlighting Growth From $ Billion To $ Billion
The expansion of fertility treatment clinics, the well-established clinical application of hCG therapies, rising rates of infertility diagnoses, the availability of injectable hormone formulations, and the growth of reproductive endocrinology practices all contributed to the growth observed during the historic period.
Growth during the forecast period is driven by higher uptake of sophisticated fertility procedures, changing maternal age patterns, broader implementation of customized treatment plans, increased funding for reproductive healthcare, and a stronger preference for outpatient fertility solutions. Key developments shaping the forecast period involve rising need for hormonal fertility medications, broader application of injectable gonadotropins, expansion of assisted reproduction techniques, heightened attention to hormonal tracking approaches, and improved patient-specific tailoring of fertility management.
Download A Free Sample Report For Comprehensive Market Insights:
Novarel Market Opportunity Drivers: What Is Creating New Revenue Potential?
The growing incidence of infertility is anticipated to propel the expansion of the Novarel market in the future. Infertility is defined as the failure to achieve a pregnancy after twelve months of consistent, unprotected intercourse or the inability to sustain a pregnancy to delivery. Escalating infertility rates globally are fueling a greater need for fertility therapies, especially ovulation induction using hCG like Novarel, as women look for ways to address difficulties with ovulation. Novarel aids in treating infertility by encouraging ovulation in women who have trouble releasing eggs and by supporting sperm production in men with low testosterone levels, thereby enhancing the likelihood of conception. For example, in April 2023, the World Health Organization reported that approximately 17.5% of the global adult population, or about one in six individuals, experiences infertility. Consequently, the rising prevalence of infertility is propelling the Novarel market.
The increase in healthcare expenditure is forecasted to drive the growth of the Novarel market in the coming period. This rise in healthcare spending results from factors like a higher frequency of chronic conditions, an aging demographic, and progress in medical technologies. Such spending supports Novarel by facilitating access to effective infertility treatments, including the use of human chorionic gonadotropin (hCG) to stimulate ovulation and enhance fertility results, thereby enabling more efficient and targeted care in reproductive health. As an illustration, in May 2024, the Office for National Statistics, a UK governmental body, indicated that total healthcare spending grew by 5.6% in nominal terms from 2022 to 2023, a notable uptick compared to the 0.9% increase seen in 2022. Hence, rising healthcare spending is advancing the Novarel market.
A higher number of drug approvals is expected to boost the growth of the Novarel market moving forward. Drug approvals describe the procedure through which regulatory bodies like the U.S. Food and Drug Administration or the European Medicines Agency assess and authorize a new medication for marketing and usage. This increase in approvals is driven by technological improvements, greater investment in healthcare, streamlined regulatory paths, a concentration on precision medicine, rising global demand for therapies, and the growth of treatments for rare diseases. Approvals for Novarel confirm its effectiveness and safety in addressing infertility, ensuring its accessibility for clinical application. For instance, in October 2024, ClinicalTrials.gov, a US-based government clinical trials database, reported that 39,710 new studies were registered in 2023, raising the cumulative total to 477,203 studies by the year’s end, compared to 38,023 new studies in 2022 that brought the cumulative number to 437,493. Thus, the escalating number of drug approvals is driving the Novarel market.
Novarel Market Segment Landscape And Growth Potential
The novarel market covered in this report is segmented –
1) By Indication: Induction Of Ovulation, Hypogonadotropic Hypogonadism, Fertility Preservation
2) By Distribution Channel: Hospital, Pharmacies, Online Pharmacies
3) By End User: Adult, Geriatric
Novarel Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the novarel market are Ferring Pharmaceuticals Inc.
Access The Complete Novarel Market Report:
Novarel Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the novarel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the novarel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model